DUX4 Gene Editing With Guide RNA for Expression Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Facioscapulohumeral muscular dystrophy (FSHD) is a debilitating condition caused by aberrant expression of the DUX4 protein, leading to muscle degeneration without a cure or effective therapy, and is also associated with B-cell leukemia and aggressive sarcoma due to DUX4 overexpression.
Innovation Solution
Compositions and systems utilizing guide RNA and effector proteins, such as base editing enzymes, are designed to target and modify the DUX4 gene, reducing its expression through methods like insertion, deletion, or substitution of nucleotides, using AAV vectors for delivery to muscle cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DUX4 gene is targeted for modification using guide RNA and effector proteins, then DUX4 expression is reduced, but the complexity of the therapeutic system increases
Solution Approach 1:
The therapeutic system is segmented into distinct functional components: guide RNA molecules with specific targeting sequences, effector proteins (such as base editing enzymes), and delivery vectors. This segmentation allows each component to be independently optimized and manufactured, reducing overall system complexity while maintaining effective DUX4 modification.
Solution Approach 2:
Guide RNA acts as an intermediary molecule that mediates between the effector protein and the DUX4 gene target. The guide RNA contains a targeting sequence that binds to the DUX4 gene and a protein binding sequence that recruits the effector protein, thereby simplifying the interaction mechanism and reducing system complexity.
2Manufacturing precision
If guide RNA with specific targeting sequences is used to modify DUX4, then gene editing precision is improved, but the difficulty of detecting and measuring target sequences increases
Solution Approach 1:
The guide RNA is designed with a specific local targeting sequence that is complementary to a unique region of the DUX4 gene. This local quality approach ensures precise binding to the correct location, improving editing precision while the uniqueness of the target sequence simplifies detection compared to searching through entire genomes.
Solution Approach 2:
The guide RNA contains a copied or synthesized version of the complementary sequence to the DUX4 gene target. This copying approach allows for precise targeting without requiring direct detection of the original target sequence, thereby improving precision while reducing detection difficulty.
3Productivity
If AAV vectors are used for delivering guide RNA and effector proteins to muscle cells, then delivery efficiency is improved, but the loss of substance (vector capacity limitations) increases
Solution Approach 1:
The AAV vector is designed to deliver only the essential partial components needed for DUX4 modification (guide RNA and effector protein), rather than attempting to deliver all possible therapeutic agents. This partial action approach maximizes delivery efficiency within vector capacity constraints while maintaining therapeutic effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively reduces DUX4 expression, potentially treating FSHD and related conditions, offering a therapeutic avenue for this currently incurable disease.
Implementation Method 1
a second region comprising a targeting sequence that is complementary to a target sequence that is within a DUX4 gene
Implementation Method 2
methods like insertion, deletion, or substitution of nucleotides, using AAV vectors for delivery to muscle cells
Data Source
AI summary
Provided herein are compositions, systems, and methods comprising effector proteins for treating DUX4 mutations. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure may leverage the activities of these effector proteins for the modification, detection, and engineering the DUX4 gene.